# Namodenoson Treatment of Advanced Pancreatic Cancer

Source: https://onco.cc/trials/nct06387342/  
OnCo record `nct06387342` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial of Namodenoson 25mg in pancreatic ductal adenocarcinoma, run by Can-Fite BioPharma, now recruiting.

## Summary

Namodenoson Treatment of Advanced Pancreatic Cancer is a phase 2 interventional study registered as NCT06387342 by Can-Fite BioPharma, with 20 participants planned, started 2024-11-10 and due to reach its primary completion in 2026-07-15. Interventions recorded: Namodenoson 25mg.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT06387342
- Phase: 2
- Setting: CF102-222PC: A Phase 2 Open-Label Study of the Safety and Activity of Namodenoson in the Treatment of Advanced Pancreatic Adenocarcinoma
- Sponsor: Can-Fite BioPharma
- Enrolled: 20

## Sources

- ClinicalTrials.gov NCT06387342: https://clinicaltrials.gov/study/NCT06387342

## Connected records

- cancers: [Pancreatic ductal adenocarcinoma](https://onco.cc/cancers/pancreatic/)
- companies: [Can-Fite BioPharma](https://onco.cc/companies/can-fite/)

---
JSON: https://onco.cc/api/v1/entities/nct06387342.json